SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:kth-136897"
 

Sökning: onr:"swepub:oai:DiVA.org:kth-136897" > Membranous expressi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005152naa a2200553 4500
001oai:DiVA.org:kth-136897
003SwePub
008131209s2013 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:59451232-9eb4-425f-8401-661993b0f9fa
009oai:DiVA.org:uu-199936
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-1368972 URI
0247 a https://doi.org/10.1038/bjc.2013.2152 DOI
0247 a https://lup.lub.lu.se/record/38047952 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1999362 URI
040 a (SwePub)kthd (SwePub)lud (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Boman, Karolinau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-kba
2451 0a Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer
264 c 2013-05-07
264 1b Springer Science and Business Media LLC,c 2013
338 a print2 rdacarrier
500 a QC 20131213
520 a Background: Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer. Methods: Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n = 100 (Cohort I) and n = 343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed. Results: Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR = 2.25 in Cohort I and 3.10 in Cohort II, adjusted HR = 2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR = 4.36, adjusted HR = 2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR = 6.19, adjusted HR = 4.60) and DSS (unadjusted HR = 8.34, adjusted HR = 7.16). Conclusion: Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a podocalyxin-like protein
653 a urothelial bladder cancer
653 a prognosis
7001 a Larsson, Anna Hu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-a_l
7001 a Segersten, Ulrikau Uppsala universitet,Urologkirurgi4 aut0 (Swepub:uu)ulriande
7001 a Kuteeva, E.4 aut
7001 a Johannesson, H.4 aut
7001 a Nodin, Björnu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)immu-bnn
7001 a Eberhard, Jakobu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-jeb
7001 a Uhlén, Mathiasu KTH,Proteomik och nanobioteknologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:kth)u1dulvmw
7001 a Malmström, Per-Unou Uppsala universitet,Urologkirurgi4 aut0 (Swepub:uu)perunoms
7001 a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji
7102 a Tumörmikromiljöb Sektion I4 org
7730 t British Journal of Cancerd : Springer Science and Business Media LLCg 108:11, s. 2321-2328q 108:11<2321-2328x 0007-0920x 1532-1827
8564 u https://www.nature.com/articles/bjc2013215.pdf
8564 u http://www.ncbi.nlm.nih.gov/pubmed/23652315?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1038/bjc.2013.215y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-136897
8564 8u https://doi.org/10.1038/bjc.2013.215
8564 8u https://lup.lub.lu.se/record/3804795
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-199936

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy